Back to results
US 2004/0110764 A1Published application
Inhibitors of prenyl-protein transferase
OwnerCraig A. Stump, Theresa M. Williamsinventors
Life of this patent
Estimating the term…
Abstract
The present invention is directed to peptidomimetic compounds that inhibit prenyl-protein transferase and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting prenyl-protein transferase and the prenylation of the oncogene protein Ras.
Claims24
A compound of the formula A:
- 52
- wherein:
- R1a is independently selected from:
- a) hydrogen,
- b) aryl, heterocycle, C3-C10 cycloalkyl, R10O—, R11S(O)m—, R10C(O)NR10—, (R10)2N—C(O)—, CN, NO2, (R10)2N—C(NR10)—, R10C(O)—, R10OC(O)—, —N(R10)2, or R11OC(O)NR10—,
- c) unsubstituted or substituted C1-C6 alkyl, unsubstituted or substituted C2-C6 alkenyl or unsubstituted or substituted C2-C6 alkynyl, wherein the substituent on the substituted C1-C6 alkyl, substituted C2-C6 alkenyl or substituted C2-C6 alkynyl is selected from unsubstituted or substituted aryl, heterocyclic, C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, R10O—, R11S(O)m—, R10C(O)NR10—, (R10)2N—C(O)—, CN, (R10)2N—C(NR10)—, R10C(O)—, R10C(O)—, —N(R10)2, and R11OC(O)—NR10—,
- or two R1as on the same carbon atom may be combined to form —(CH2)t—;
- R1b and R1c are independently selected from:
- a) hydrogen,
- b) aryl, heterocycle, C3-C10 cycloalkyl, (R10)2N—C(O)—, (R10)2N— C(NR10)—, R10C(O)— or R10OC(O)—, and
- c) unsubstituted or substituted C1-C6 alkyl, unsubstituted or substituted C2-C6 alkenyl or unsubstituted or substituted C2-C6 alkynyl, wherein the substituent on the substituted C1-C6 alkyl, substituted C2-C6 alkenyl or substituted C2-C6 alkynyl is selected from unsubstituted or substituted aryl, heterocyclic, C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, one or more fluorines, R10O—, R11S(O)m—, R10C(O)NR10—, (R10)2N—C(O)—, CN, (R10)2N—C(NR10)—, R10C(O)—, R10OC(O)—, —N(R10)2, and R11OC(O)—NR10—;
- R2 and R3 are independently selected from H;
- unsubstituted or substituted C1-8 alkyl, unsubstituted or substituted C2-8 alkenyl, unsubstituted or substituted C2-8 alkynyl, unsubstituted or substituted aryl, unsubstituted or substituted heterocycle,
- 53
- wherein the substituted group is substituted with one or more of:
- 1) aryl or heterocycle, unsubstituted or substituted with:
- a) C1-4 alkyl,
- b) (CH2)pOR6,
- c) (CH2)pNR6R7,
- d) halogen,
- e) CN,
- 2) C3-6 cycloalkyl,
- 3) OR6,
- 4) SR4, S(O)R4, SO2R4,
- 54
- 15) N3, or
- 16) F;
- or
- R2 and R3 are attached to the same carbon atom and are combined to form —(CH2)u— wherein one of the carbon atoms is optionally replaced by a moiety selected from O, S(O)m, —NC(O)—, and —N(COR10)—;
- and
- R4 is selected from C1-4 alkyl, C3-6 cycloalkyl, heterocycle, aryl, unsubstituted or substituted with:
- 55
- R5, R6 and R7 are independently selected from:
- 1) hydrogen,
- 2) R10C(O)—, or R10OC(O)—, and
- 3) C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-6 cycloalkyl, heterocycle, aryl, aroyl, heteroaroyl, arylsulfonyl, heteroarylsulfonyl, unsubstituted or substituted with one or more substituents selected from:
- 56
- R6 and R7 may be joined in a ring;
- and independently,
- R5 and R7 may be joined in a ring;
- R8 is independently selected from:
- a) hydrogen,
- b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 perfluoroalkyl, F, Cl, Br, R12O—, R11S(O)m—, R10C(O)NR10—, (R10)2NC(O)—, R102N—C(NR10)—, CN, NO2, R10C(O)—, R10OC(O)—, —N(R10)2, or R11OC(O)NR10—, and
- c) C1-C6 alkyl unsubstituted or substituted by unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 perfluoroalkyl, F, Cl, Br, R10O—, R11S(O)m—, R10C(O)NH—, (R10)2NC(O)—, R102N—C(NR10)—, CN, R10C(O)—, R10OC(O)—, —N(R10)2, or R10OC(O)NH—;
- R9 is independently selected from:
- a) hydrogen,
- b) C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 perfluoroalkyl, F, Cl, Br, R10O—, R11S(O)m—, R10C(O)NR10—, (R10)2NC(O)—, R102N—C(NR10)—, CN, NO2, R10C(O)—, R10OC(O)—, —N(R10)2, or R11OC(O)NR10—, and
- c) C1-C6 alkyl unsubstituted or substituted by C1-C6 perfluoroalkyl, F, Cl, Br, R10O—, R11S(O)m—, R10C(O)NR10—, (R10)2NC(O)—, R102N—C(NR10)—, CN, R10C(O)—, R10OC(O)—, —N(R10)2, or R11OC(O)NR10—;
- R10 is independently selected from hydrogen, C1-C6 alkyl, C1-C6 alkyl substituted with one or more fluorines, benzyl, unsubstituted or substituted aryl and unsubstituted or substituted heterocycle;
- R11 is independently selected from C1-C6 alkyl, C1-C6 alkyl substituted with one or more fluorines, unsubstituted or substituted aryl and unsubstituted or substituted heterocycle;
- R12 is independently selected from hydrogen, C1-C6 alkyl, C1-C6 alkyl substituted with one or more fluorines, unsubstituted or substituted benzyl, unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, and C1-C6 alkyl substituted with unsubstituted or substituted aryl or unsubstituted or substituted heterocycle;
- G1, G2 and G3 are independently selected from (R2,R3) and O;
- V is selected from:
- a) heterocycle, and
- b) aryl;
- W is S(O)m, O or CH2;
- X is selected from:
- a bond, —C(O)—, —NR10C(O)—, —N(R10)S(O)2— and S(O)2;
- Y is selected from a bond, —C(O)—, —C(O)NR10—, —C(O)O—, —(CR1c2)— and —S(O)m;
- Z is selected from unsubstituted or substituted aryl and unsubstituted or substituted heterocycle, wherein the substituted aryl or substituted heterocycle is substituted with one or more of:
- 1) C1-8 alkyl, C2-8 alkenyl or C2-8 alkynyl, unsubstituted or substituted with:
- a) C1-4 alkoxy,
- b) NR6R7,
- c) C3-6 cycloalkyl,
- d) aryl or heterocycle,
- e) HO,
- f) —S(O)mR4,
- g) —C(O)NR6R7, or
- h) one or more fluorines;
- 2) substituted or unsubstituted aryl or substituted or unsubstituted heterocycle,
- 3) halogen,
- 4) OR6,
- 5) NR6R7,
- 6) CN,
- 7) NO2,
- 8) CF3;
- 9) —S(O)mR4,
- 10) —OS(O)2R4,
- 11) —C(O)NR6R7,
- 12) —C(O)OR6, or
- 13) C3-C6 cycloalkyl;
- m is independently 0, 1 or 2;
- p is independently 0, 1, 2, 3 or 4;
- q is 1 or 2;
- r is 0 to 5;
- s is 1 or 2;
- t is 2, 3, 4, 5 or 6;
- and
- u is 2, 3, 4 or 5;
- or a pharmaceutically acceptable salt or stereoisomer thereof.
87 more elements
A compound which is selected from:
- (3R) 5-{1-[4-(3-Chlorophenyl)-3-oxo-piperazin-1-yl]-methanoyl}-3-(4-cyanophenyl)-2,3-dihydro-imidazo[2,1-b]thiazole
- (3S) 5-{1-[4-(3-Chlorophenyl)-3-oxo-piperazin-1-yl]-methanoyl}-3-(4-cyanophenyl)-2,3-dihydro-imidazo[2,1-b]thiazole
- 5-[1-[4-(3-chlorophenyl)-3-oxo-piperazin-1-ylmethyl]-3-(4-cyanophenyl)-2,3-dihydro-imidazo[2,1-b]thiazole
- 5-{1-[4-(3-Chlorophenyl)-piperazin-1-yl]-methanoyl}-3-(4-cyanophenyl)-2,3-dihydro-imidazo[2,1-b]thiazole
- (3R) 5-{1-[(2S) 2-butyl-4-(3-methoxyphenyl)-5-oxo-piperazin-1-yl]-methanoyl}-3-(4-cyanophenyl)-2,3-dihydro-imidazo[2,1-b]thiazole
- (3S) 5-{1-[(2S) 2-butyl-4-(3-methoxyphenyl)-5-oxo-piperazin-1-yl]-methanoyl}-3-(4-cyanophenyl)-2,3-dihydro-imidazo[2,1-b]thiazole
- (3R) 3-(4-Cyanophenyl)-5-{1-[(2S) 4-(3-methoxyphenyl)-5-oxo-2-(2-thienylmethyl)-1-piperazinyl]-methanoyl}-2,3-dihydro-imidazo[2,1-b]thiazole
- (3S) 3-(4-Cyanophenyl)-5-{1-[(2S) 4-(3-methoxyphenyl)-5-oxo-2-(2-thienylmethyl)-1-piperazinyl]-methanoyl}-2,3-dihydro-imidazo[2,1-b]thiazole
- (1R,S) (3R) 5-{1-[4-(3-Chlorophenyl)-3-oxo-piperazin-1-yl]-methanoyl}-3-(4-cyanophenyl)-1-oxo-2,3-dihydro-imidazo[2,1-b]thiazole
- (1R,S) (3S) 5-{1-[4-(3-Chlorophenyl)-3-oxo-piperazin-1-yl]-methanoyl}-3-(4-cyanophenyl)-1-oxo-2,3-dihydro-imidazo[2,1-b]thiazole
- (3R) 5-{1-[4-(3-Chlorophenyl)-3-oxo-piperazin-1-yl]-methanoyl}-3-(4-cyanophenyl)-1,1-dioxo-2,3-dihydro-imidazo[2,1-b]thiazole
- (3S) 5-{1-[4-(3-Chlorophenyl)-3-oxo-piperazin-1-yl]-methanoyl}-3-(4-cyanophenyl)-1,1-dioxo-2,3-dihydro-imidazo[2,1-b]thiazole
- 3-{1-[4-(3-Chlorophenyl)-3-oxo-piperazin-1-yl]-methyl}-5-(4-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine
- (5R) 3-{1-[4-(3-chlorophenyl)-3-oxo-piperazin-1-yl]-methanoyl}-5-(4-cyanophenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole
- (5S) 3-{1-[4-(3-chlorophenyl)-3-oxo-piperazin-1-yl]-methanoyl}-5-(4-cyanophenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole
- 5-{1-[4-(3-Chlorophenyl)-3-oxo-piperazin-1-yl]-methanoyl}-3-(4-cyanophenyl)-3-methyl-2,3-dihydroimidazo[2,1-b]thiazole
- 5-{1-[4-(2-Bromo-5-(allyloxy)benzyl)-3-oxo-piperazin-1-yl]-methanoyl}-3-(4-cyanophenyl)-2,3-dihydro-imidazo[2,1-b]thiazole
- 3-{1-[4-(2-chloro-5-hydroxybenzyl)-3-oxo-piperazin-1-yl]-methanoyl}-5-(4-cyano-3-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole
- or a pharmaceutically acceptable salt or stereoisomer thereof.
16 more elements
Dependencies are inferred from the claim text.